Posters

    Evidence on Smoking and Chronic Obstructive Pulmonary Disease

    Forey, B. A.; Lee, P. N.; Lama, N.; Sponsiello-Wang, Z.; Weitkunat, R.

    Conference date
    Sep 12, 2010
    Conference name
    American College of Epidemiology (ACE) Meeting 2010
    Link to more information
    Topic
    Summary

    Purpose: To review available epidemiological data on the relationship of chronic obstructive pulmonary disease (COPD) to smoking. Methods: Epidemiological studies published up to 2006 relating smoking to the prevalence or incidence of COPD or closely related outcomes were reviewed. Meta-analytic methods were used to estimate the overall relative risk (RR). Results: A total of 117 independent studies, conducted mainly in Europe, North America, and Asia, were identified: 69 cross-sectional, 34 prospective, and 14 case-control studies. An association of COPD risk with smoking was consistently seen. Random-effects RR estimates compared to never smokers were 2.85 (95% confidence interval CI 2.60-3.13) for ever smoking and 3.48 (95% CI 3.07-3.94) for current smoking. Risk increased monotonically with increasing amount smoked with RRS of 2.77, 5.91, and 8.76 for approximately 5, 20, and 45 cigarettes per day and RRS of 1.25, 2.51, and 3.88 for approximately 5, 20, and 45 pack-years. There was marked heterogeneity between study-specific RR estimates. RRS were higher for studies of mortality and incidence, particularly for studies excluding asthma from their definition of COPD, and lower for studies of prevalent COPD, especially those based on lung function criteria. Conclusion: There is highly consistent evidence of an association of COPD with smoking, but the magnitude of the observed association varies.

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.